Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Trends in Cancer|December 7, 2020
Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and ResistanceMarina Bacci, Nicla Lorito, Alfredo Smiriglia, et al.
Trends in Molecular Medicine|June 3, 2026
Under pressure: peroxisomes in cancer therapy resistanceNicla Lorito, Francesca Bonechi, Elisabetta Romano, et al.
Iscience|November 30, 2023
Sex difference in liver diseases: How preclinical models help to dissect the sex-related mechanisms sustaining NAFLD and hepatocellular carcinomaAlfredo Smiriglia, Nicla Lorito, Marina Serra, et al.
Molecular and Cellular Biochemistry|May 23, 2025
CD44 and SLC1A2 are commonly regulated but do not form a fusion transcript in ER+ breast cancerFrancesca Bonechi, Marina Bacci, Nicla Lorito, et al.
Cell Death & Disease|January 31, 2025
Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic diseaseAlfredo Smiriglia, Nicla Lorito, Marina Bacci, et al.
Cancer Treatment Reviews|May 27, 2022
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedsideIcro Meattini, Lorenzo Livi, Nicla Lorito, et al.
Breast Cancer Research : BCR|June 23, 2025
In vivo imaging of the spatial heterogeneity of intratumoral acidosis (pH) as a marker of the metastatic phenotype in breast cancerAlessia Corrado, Nicla Lorito, Annasofia Anemone, et al.
Cell Death & Disease|November 10, 2025
Lead induces cell-autonomous proliferation and metabolic reprogramming of hepatocytesMarina Serra, Alfredo Smiriglia, Cristina Migliore, et al.
Cells|March 14, 2020
Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib.Nicla Lorito, Marina Bacci, Alfredo Smiriglia, et al.
Molecular Cancer Therapeutics|September 27, 2018
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate ModelsFlorian Handle, Martin Puhr, Georg Schaefer, et al.
Pageof 2